又一家跨国药企在华人员优化这次是默沙东中国糖尿病业务

第一财经11-19

继强生之后，又一家跨国药企传出裁员消息。有市场消息称，默沙东中国糖尿病业务因药品集采在裁员中。　　第一财经记者向默沙东中国官方求证，截至发稿时尚未获得回复。　　不过，第一财经记者从默沙东内部人士证实了该消息的真实性，但裁员幅度暂不详。　　默沙东旗下有三款糖尿病药物，分别是西格列汀、西格列汀二甲双胍、艾托格列净，前两款药物是公司糖尿病业务的主要销售来源。　　糖尿病是一种慢性病，当胰岛素产生不足或无法...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2484434219?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-11-19 20:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2484434219","market":"hk","top_or_hot":-1,"title":"又一家跨国药企在华人员优化 这次是默沙东中国糖尿病业务","media":"第一财经","content":"<div>\n<p>继强生之后，又一家跨国药企传出裁员消息。有市场消息称，默沙东中国糖尿病业务因药品集采在裁员中。　　第一财经记者向默沙东中国官方求证，截至发稿时尚未获得回复。　　不过，第一财经记者从默沙东内部人士证实了该消息的真实性，但裁员幅度暂不详。　　默沙东旗下有三款糖尿病药物，分别是西格列汀、西格列汀二甲双胍、艾托格列净，前两款药物是公司糖尿病业务的主要销售来源。　　糖尿病是一种慢性病，当胰岛素产生不足或无法...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202411193244442093.html\">网页链接</a>\n\n</div>\n","source":"stock_eastmoney","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>又一家跨国药企在华人员优化 这次是默沙东中国糖尿病业务</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n又一家跨国药企在华人员优化 这次是默沙东中国糖尿病业务\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-19 20:23 北京时间&nbsp;&nbsp;&nbsp;<a href=http://finance.eastmoney.com/a/202411193244442093.html><strong>第一财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>继强生之后，又一家跨国药企传出裁员消息。有市场消息称，默沙东中国糖尿病业务因药品集采在裁员中。　　第一财经记者向默沙东中国官方求证，截至发稿时尚未获得回复。　　不过，第一财经记者从默沙东内部人士证实了该消息的真实性，但裁员幅度暂不详。　　默沙东旗下有三款糖尿病药物，分别是西格列汀、西格列汀二甲双胍、艾托格列净，前两款药物是公司糖尿病业务的主要销售来源。　　糖尿病是一种慢性病，当胰岛素产生不足或无法...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202411193244442093.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B4R5TH58.HKD","symbol_name":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","start_time":0,"source_url":"http://finance.eastmoney.com/a/202411193244442093.html","article_id":"2484434219","we_media_id":null,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202411193244442093.html","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2484434219","pubTimestamp":1732019027,"sourceInfo":{"source_id":"stock_eastmoney","name":"东方财富"},"weMediaInfo":null,"summary":"继强生之后，又一家跨国药企传出裁员消息。有市场消息称，默沙东中国糖尿病业务因药品集采在裁员中。第一财经记者向默沙东中国官方求证，截至发稿时尚未获得回复。不过，第一财经记者从默沙东内部人士证实了该消息的真实性，但裁员幅度暂不详。默沙东旗下有三款糖尿病药物，分别是西格列汀、西格列汀二甲双胍、艾托格列净，前两款药物是公司糖尿病业务的主要销售来源。","collect":0,"end_time":0,"defaultTopTitle":"eastmoney.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","LU0265550359.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A2\" (USD) ACC","MRK":"默沙东","LU1116320901.HKD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A6\" (HKD) INC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU1917777945.USD":"安联专题基金Cl AT Acc","SG9999014575.USD":"UOB UNITED INCOME FOCUS TRUST FUND (USDHDG) INC","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","BK4516":"特朗普概念","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU1037948897.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (HKD) INC","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","BK4585":"ETF&股票定投概念","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","LU2023250843.SGD":"Allianz Thematica Cl AT Acc H2-SGD","BK4533":"AQR资本管理(全球第二大对冲基金)","LU1037948541.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (HKD) ACC","LU1941712264.USD":"ALLIANZ PET AND ANIMAL WELLBEING \"A\" (USD) INC","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","LU0965509010.AUD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (AUDHDG) INC","LU2361044949.HKD":"WELLINGTON US QUALITY GROWTH \"A\" (HKD) ACC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","BK4588":"碎股","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","BK4550":"红杉资本持仓","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","SG9999014567.USD":"UOB UNITED INCOME FOCUS TRUST FUND (USD) ACC","SG9999001176.USD":"United Global Healthcare Acc USD","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","LU1066051811.HKD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (HKD) INC","LU2361045086.USD":"WELLINGTON US QUALITY GROWTH \"A\" (USD) ACC","LU0985320562.USD":"NORDEA 1 GLOBAL STARS EQUITY \"BP\" (USD) ACC","LU1116320737.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A6\" (USD) INC","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","SG9999014542.SGD":"United Income Focus Trust Acc SGD","LU1066051225.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AC\" (USD) ACC"},"translate_title":"Another multinational pharmaceutical company optimizes its personnel in China This time it is Merck's China diabetes business","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRK":1},"content_text":"继强生之后，又一家跨国药企传出裁员消息。有市场消息称，默沙东中国糖尿病业务因药品集采在裁员中。　　第一财经记者向默沙东中国官方求证，截至发稿时尚未获得回复。　　不过，第一财经记者从默沙东内部人士证实了该消息的真实性，但裁员幅度暂不详。　　默沙东旗下有三款糖尿病药物，分别是西格列汀、西格列汀二甲双胍、艾托格列净，前两款药物是公司糖尿病业务的主要销售来源。　　糖尿病是一种慢性病，当胰岛素产生不足或无法被有效利用时，就会出现糖尿病。血糖升高是糖尿病失控的常见后果，随着时间的推移会对人体的其它系统和器官带来严重损害，主流的糖尿病药物包括二甲双胍、格列奈类、磺脲类、α-糖苷酶抑制剂、TZD类、SGLT-2抑制剂、DPP-4抑制剂、GLP-1激动剂等非胰岛素类药物以及胰岛素类药物。GLP-1激动剂是全球最大的降糖药品类。　　默沙东的西格列汀是全球首款上市的DPP-4抑制剂，早在2006年获批在美国上市。2009年进入中国市场销售。西格列汀二甲双胍是西格列汀和二甲双胍的复方制剂。早年，由于长时间无竞争对手，西格列汀在全球市场的销售一度颇为抢眼，销售额逐渐攀升。　　从默沙东的全球收入看，这些年受制于专利悬崖以及市场激烈竞争，西格列汀、西格列汀二甲双胍这两款药物的销售额已有所萎缩。　　如2022年，西格列汀、西格列汀二甲双胍合计实现销售额45.13亿美元。2023年，这两款药物合计销售额已减少至33.66亿美元。　　在中国市场，西格列汀口服常释剂型、西格列汀二甲双胍正被列入第十批国家组织药品集中采购范围。11月1日，国家组织药品联合采购办公室已在开展第十批国家组织药品集中采购相关药品信息填报工作。　　根据米内网数据，西格列汀口服常释剂型2023年在中国公立医疗机构终端的销售额超过20亿元，虽然这款药物的仿制药企业数量超过30家，但作为原研厂家的默沙东销售占比仍超九成。　　对于默沙东而言，西格列汀、西格列汀二甲双胍这两款药物一旦集采的话，将面临与其他仿制药企激烈价格竞争，其在中国公立医疗机构的市场份额面临被瓜分风险。（文章来源：第一财经）","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"Executive Changes","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2484434219"}

又一家跨国药企在华人员优化 这次是默沙东中国糖尿病业务

精彩评论

又一家跨国药企在华人员优化这次是默沙东中国糖尿病业务